 |
|
A Double-blind Study of Subcutaneous Dihydroergotamine vs Subcutaneous Sumatriptan in the Treatment of Acute Migraine
Paul Winner, DO;
Orlando Ricalde, MD;
Bruce Le Force, MD;
Joel Saper, MD;
Betty Margul, MD
Arch Neurol. 1996;53(2):180-184.
Abstract
| |
Objective
To assess the efficacy and tolerability of subcutaneous dihydroergotamine mesylate (DHE-45) vs subcutaneous sumatriptan succinate (Imitrex) for the treatment of acute migraine with or without aura.
Design
Double-blind, randomized trial with parallel treatment arms.
Setting
Clinics and private neurology practices.
Subjects
Patients of either sex, with migraine with or without aura, between the ages of 18 and 65 years.
Interventions
Patients with moderate or severe head pain were randomized to receive either 1 mg of subcutaneous dihydroergotamine mesylate or 6 mg of subcutaneous sumatriptan succinate. Patients rated head pain, functional ability, nausea, and vomiting at baseline and at 0.5, 1, 2,4, and 24 hours after the injection. Presence or absence of headache at 3 hours was calculated from collected data. If pain persisted after 2 hours, a second injection of the same study medication was allowed, and self-ratings were repeated 30 and 60 minutes later. Follow-up data were collected at 24 hours.
Main Outcome Measures
Relief of head pain and recurrence of successfully treated headache.
Results
There were 295 evaluable patients. At 2 hours, 73.1% of the patients treated with dihydroergotamine and 85.3% of those treated with sumatriptan had relief (P=.002). There was no statistical difference in headache relief between the groups at 3 or 4 hours. Headache relief was achieved by 85.5% of those treated with dihydroergotamine and by 83.3% of those treated with sumatriptan by 4 hours. By 24 hours 89.7% of dihydroergotamine-treated patients and 76.7% of sumatriptan-treated patients had relief (P=.004). Headache recurred within 24 hours after treatment in 45% of the sumatriptan-treated patients and in 17.7% of the dihydroergotamine-treated patients (P .001).
Conclusions
Both sumatriptan and dihydroergotamine were effective in aborting migraine headaches. Headache recurrence was two and a half times as likely with sumatriptan as with dihydroergotamine.
Author Affiliations
From the Palm Beach Headache Center, West Palm Beach, Fla (Dr Winner), the Departments of Neurology, Keesler Medical Center, Keesler Air Force Base, Miss (Dr Ricalde), and Lackland Medical Center, Lackland Air Force Base, Tex (Dr Le Force), the Michigan Head Pain and Neurological Institute, Ann Arbor (Dr Saper), and Sandoz Pharmaceuticals, East Hanover, NJ (Dr Margul). Dr Le Force is now in private practice, San Antonio, Tex, and Dr Ricalde is at the Department of Neurology, Tulane University Medical School, New Orleans, La. For a list of the other participants in the study, see box on page 184.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
History of the Use of Ergotamine and Dihydroergotamine in Migraine From 1906 and Onward
Tfelt-Hansen and Koehler
Cephalalgia 2008;28:877-886.
ABSTRACT
| FULL TEXT
Tactile-Induced Ultrasonic Vocalization in the Rat: A Novel Assay to Assess Anti-Migraine Therapies in vivo
Martino and Perkins
Cephalalgia 2008;28:723-733.
ABSTRACT
| FULL TEXT
Randomized trial of IV dexamethasone for acute migraine in the emergency department
Friedman et al.
Neurology 2007;69:2038-2044.
ABSTRACT
| FULL TEXT
Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life
Lipton et al.
Neurology 2005;65:S50-S58.
ABSTRACT
| FULL TEXT
A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines
Friedman et al.
Neurology 2005;64:463-468.
ABSTRACT
| FULL TEXT
Migraine: pharmacotherapy in the emergency department
Kelly
Emerg. Med. J. 2000;17:241-245.
ABSTRACT
| FULL TEXT
Use and Overuse of Sumatriptan. Pharmacoepidemiological Studies Based on Prescription Register and Interview Data
Gaist
Cephalalgia 1999;19:735-761.
A triptan too far?
GOADSBY
J. Neurol. Neurosurg. Psychiatry 1998;64:143-147.
FULL TEXT
Subcutaneous Dihydroergotamine vs Subcutaneous Sumatriptan
Catarci and Cerbo
Arch Neurol 1996;53:1215-1215.
ABSTRACT
Subcutaneous Dihydroergotamine vs Subcutaneous Sumatriptan-Reply
Winner and Saper
Arch Neurol 1996;53:1215-1216.
ABSTRACT
SUMATRIPTAN VS. DIHYDROERGOTAMINE FOR MIGRAINE
JWatch General 1996;1996:6-6.
FULL TEXT
|
